Related Experiment Videos
[HGF as a key molecule in cardiovascular diseases]
M Aoki1, T Ogihara, R Morishita
1Department of Geriatric Medicine, Osaka University Medical School.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|January 5, 2002
Summary
Hepatocyte growth factor (HGF) shows promise as an endothelial growth factor for cardiovascular diseases. HGF-based gene therapy is emerging for conditions like restenosis and ischemic diseases, with early clinical trials underway.
Area of Science:
- Cardiovascular Biology
- Regenerative Medicine
- Gene Therapy
Context:
- Hepatocyte growth factor (HGF) is recognized for its significant role in endothelial cell function.
- Its physiological importance in atherosclerosis, restenosis, and angiogenesis is well-established.
- Existing gene therapies, like VEGF for restenosis, demonstrate the potential of such strategies.
Purpose:
- To explore the therapeutic potential of Hepatocyte Growth Factor (HGF) in cardiovascular diseases.
- To highlight the emerging applications of HGF-based gene therapy.
- To discuss the future prospects of HGF in treating various vascular and organ-specific conditions.
Summary:
- Hepatocyte growth factor (HGF) is a potent endothelial growth factor with critical roles in cardiovascular pathologies.
- Gene therapy utilizing HGF is being investigated, with initial clinical trials commencing in Japan for atherosclerotic occlusive disease (ASO).
- This approach holds promise for future treatments of restenosis, graft failure, cardiomyopathy, and renal failure.
Impact:
- HGF-based therapies are expected to offer novel treatment options for a range of cardiovascular and organ-specific diseases.
- The advancement of HGF gene therapy could lead to improved patient outcomes in conditions currently lacking effective treatments.
- Early clinical applications suggest a significant therapeutic impact in the near future for vascular and ischemic diseases.